At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MLYS Mineralys Therapeutics, Inc.
Post-Mkt 11-10 19:37:11 EST
15.52
-0.29
-1.83%
盘后15.52
+0.000.00%
19:30 EST
High16.52Low15.05Vol1.72M
Open15.48D1 Closing15.81Amplitude9.30%
Mkt Cap1.37BTradable Cap1.03BTotal Shares88.16M
T/O26.60MT/O Rate2.59%Tradable Shares66.36M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mineralys Therapeutics (MLYS) Could Be 66% Undervalued Following Long Term Trial Data
Simply Wall St.  ·  11-09 11:20
Mineralys Therapeutics (MLYS) Could Be 66% Undervalued Following Long Term Trial Data
Mineralys Therapeutics announces long-term results from Transform-HTN trial
TIPRANKS  ·  11-09 05:50
Mineralys Therapeutics announces long-term results from Transform-HTN trial
Mineralys' Lorundrostat Lowers Systolic Blood Pressure by 17.8 mmHg at 48 Weeks in Extension Trial
Reuters  ·  11-09 05:35
Mineralys' Lorundrostat Lowers Systolic Blood Pressure by 17.8 mmHg at 48 Weeks in Extension Trial
Mineralys Therapeutics Grants New Employee 14,880 Stock Options, 11,160 Restricted Stock Units
Reuters  ·  11-06
Mineralys Therapeutics Grants New Employee 14,880 Stock Options, 11,160 Restricted Stock Units
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  11-06
Mineralys Therapeutics Reports Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Stifel Nicolaus Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TIPRANKS  ·  11-05
Stifel Nicolaus Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics Presents Lorundrostat Efficacy and Safety Data in Uncontrolled and Resistant Hypertension
Reuters  ·  11-05
Mineralys Therapeutics Presents Lorundrostat Efficacy and Safety Data in Uncontrolled and Resistant Hypertension
Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Reuters  ·  11-05
Mineralys Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary
Mineralys Therapeutics Participates in Fireside Chats at Three Investor Conferences
Reuters  ·  11-04
Mineralys Therapeutics Participates in Fireside Chats at Three Investor Conferences
Mineralys Therapeutics Acquires Lorundrostat Intellectual Property from Tanabe Pharma
Reuters  ·  10-30
Mineralys Therapeutics Acquires Lorundrostat Intellectual Property from Tanabe Pharma
Mineralys Therapeutics Schedules Third-Quarter Financial Results Call
Reuters  ·  10-29
Mineralys Therapeutics Schedules Third-Quarter Financial Results Call
Mineralys' Lorundrostat Meets Blood Pressure Endpoint in Phase 2 Kidney Disease Trial
Reuters  ·  10-28
Mineralys' Lorundrostat Meets Blood Pressure Endpoint in Phase 2 Kidney Disease Trial
Mineralys Therapeutics Announces Publication of Phase 2 Explore-Ckd Trial Results for Lorundrostat in Kidney International
THOMSON REUTERS  ·  10-28
Mineralys Therapeutics Announces Publication of Phase 2 Explore-Ckd Trial Results for Lorundrostat in Kidney International
Phase 3 Kidney Data Might Change The Case For Investing In Mineralys Therapeutics (MLYS)
Simply Wall St.  ·  10-27
Phase 3 Kidney Data Might Change The Case For Investing In Mineralys Therapeutics (MLYS)
Is Mineralys Therapeutics (MLYS) A Bargain On Phase 3 Lorundrostat Data?
Simply Wall St.  ·  10-26
Is Mineralys Therapeutics (MLYS) A Bargain On Phase 3 Lorundrostat Data?
Mineralys' Lorundrostat Lowers Blood Pressure in Kidney Disease Patients in Phase 3 Trial
Reuters  ·  10-23
Mineralys' Lorundrostat Lowers Blood Pressure in Kidney Disease Patients in Phase 3 Trial
Mineralys Therapeutics Grants Director Lonnel Coats 12,400 Restricted Stock Units
Reuters  ·  10-21
Mineralys Therapeutics Grants Director Lonnel Coats 12,400 Restricted Stock Units
Mineralys Therapeutics Appoints Kristine Peterson and Lonnel Coats to Board
Reuters  ·  10-20
Mineralys Therapeutics Appoints Kristine Peterson and Lonnel Coats to Board
Mineralys Therapeutics Expands Its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
THOMSON REUTERS  ·  10-20
Mineralys Therapeutics Expands Its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats
Did Phase 3 Blood Pressure Data Just Shift Mineralys Therapeutics Stock Investment Narrative?
Simply Wall St.  ·  10-19
Did Phase 3 Blood Pressure Data Just Shift Mineralys Therapeutics Stock Investment Narrative?

Introduction

Company Name.
Mineralys Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Issue price:
--